NO20034166L - Molekyl¶re konjugater for anvendelse ved behandling av cancer - Google Patents

Molekyl¶re konjugater for anvendelse ved behandling av cancer

Info

Publication number
NO20034166L
NO20034166L NO20034166A NO20034166A NO20034166L NO 20034166 L NO20034166 L NO 20034166L NO 20034166 A NO20034166 A NO 20034166A NO 20034166 A NO20034166 A NO 20034166A NO 20034166 L NO20034166 L NO 20034166L
Authority
NO
Norway
Prior art keywords
cancer
treatment
molecular conjugates
conjugates
molecular
Prior art date
Application number
NO20034166A
Other languages
English (en)
Other versions
NO20034166D0 (no
Inventor
James D Mcchesney
Madhavi C Chander
Teruna J Siahaan
Christine R Xu
Original Assignee
Napro Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Napro Biotherapeutics Inc filed Critical Napro Biotherapeutics Inc
Publication of NO20034166D0 publication Critical patent/NO20034166D0/no
Publication of NO20034166L publication Critical patent/NO20034166L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20034166A 2001-03-23 2003-09-19 Molekyl¶re konjugater for anvendelse ved behandling av cancer NO20034166L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27824301P 2001-03-23 2001-03-23
PCT/US2002/009417 WO2002076448A1 (en) 2001-03-23 2002-03-25 Molecular conjugates for use in treatment of cancer

Publications (2)

Publication Number Publication Date
NO20034166D0 NO20034166D0 (no) 2003-09-19
NO20034166L true NO20034166L (no) 2003-11-20

Family

ID=23064243

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034166A NO20034166L (no) 2001-03-23 2003-09-19 Molekyl¶re konjugater for anvendelse ved behandling av cancer

Country Status (8)

Country Link
US (2) US6825166B2 (no)
EP (1) EP1383492A4 (no)
JP (2) JP2004528309A (no)
AU (1) AU2002254400B2 (no)
CA (1) CA2441484A1 (no)
IL (2) IL157993A0 (no)
NO (1) NO20034166L (no)
WO (1) WO2002076448A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1404334A4 (en) * 2001-05-15 2005-02-02 Faulk Pharmaceuticals Inc TARGETED ADMINISTRATION OF BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER
JP2005514322A (ja) * 2001-05-15 2005-05-19 ページ ダブル フォーク 生体影響性成分と細胞標的化成分の所定の比を有する、実質的に均質な生体影響性物質、このような物質を作製するための方法、及びその使用法
DK1506203T3 (da) 2002-08-23 2007-05-14 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004060403A2 (en) 2003-01-06 2004-07-22 Angiochem Inc. Aprotinin and anglos as carriers across the blood-brain barrier
US20060246161A1 (en) * 2003-02-21 2006-11-02 Hongtao Xing Method of making medicament for treating anemia
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005030150A2 (en) 2003-09-25 2005-04-07 Tapestry Pharmaceuticals, Inc. 9,10-α,α-OH-TAXANE ANALOGS AND METHODS FOR PRODUCTION THEREOF
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
PT1859041E (pt) * 2005-02-18 2012-06-19 Angiochem Inc Moléculas para transportar um composto através da barreira hematoencefálica
WO2006124737A2 (en) * 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
EP1907009A4 (en) * 2005-07-15 2009-09-02 Angiochem Inc USE OF APROTININ POLYPEPTIDES AS CARRIER IN PHARMACEUTICAL CONJUGATES
MX2008008119A (es) * 2005-12-21 2008-09-24 Tapestry Pharmaceuticals Inc Procesos para derivados de taxano y compuestos intermedios utiles en los mismos.
US20090156828A1 (en) * 2005-12-21 2009-06-18 Tapestry Pharmaceuticals, Inc. Novel Compounds and Methods for Forming Taxanes and Using the Same
WO2007126893A2 (en) * 2006-03-27 2007-11-08 Tapestry Pharmaceuticals, Inc. A convergent process for the synthesis of taxane derivatives
WO2008070347A2 (en) * 2006-10-27 2008-06-12 Regents Of The University Of Minnesota Betulin-peptide conjugates
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
JP5860698B2 (ja) * 2008-04-18 2016-02-16 アンジオケム，インコーポレーテッド パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
WO2010043049A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
EP2370471B1 (en) 2008-12-05 2017-02-22 Angiochem Inc. Neurotensin conjugate and uses thereof
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
CA2759129C (en) 2009-04-20 2018-12-11 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
US9333189B2 (en) * 2010-02-03 2016-05-10 Oncbiomune, Inc. Taxane- and taxoid-protein compositions
RU2606016C2 (ru) 2011-01-14 2017-01-10 Редвуд Байосайнс, Инк. Меченые альдегидом полипептиды иммуноглобулина и способы их применения
CN103763928B (zh) * 2011-06-06 2016-09-21 阿伯疗法责任有限公司 癌症化疗剂的酸不稳定的亲脂性前体药物
PL2543357T3 (pl) * 2011-07-07 2018-08-31 Holy Stone Healthcare Co.,Ltd. Kompozycja do zastosowania w leczeniu i zapobieganiu zaburzeniom związanym ze stanem zapalnym
WO2013188763A1 (en) * 2012-06-15 2013-12-19 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2944591A1 (de) * 1979-11-05 1981-05-14 Wacker-Chemie GmbH, 8000 München Fluessigkristalline phasen aufweisende zusammensetzungen
US5144011A (en) 1981-06-26 1992-09-01 Boston University Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US5108987A (en) 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
GB2116979B (en) 1982-02-25 1985-05-15 Ward Page Faulk Conjugates of proteins with anti-tumour agents
US4522750A (en) 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5728383A (en) 1987-10-05 1998-03-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment of tumors of the central nervous system with immunotoxins
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
CA2075927A1 (en) 1990-02-16 1991-08-17 Victor A. Raso Hybrid reagents capable of selectively releasing molecules into cells
US5762932A (en) 1990-04-26 1998-06-09 University Of Iowa Research Foundation Combined treatment of iron depletion and IgG antibody
GB9017024D0 (en) 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5393737A (en) 1992-08-20 1995-02-28 Health Research, Inc. Cytotoxic drug conjugates for treatment of neoplastic diseases
US5948919A (en) 1993-02-05 1999-09-07 Napro Biotherapeutics, Inc. Paclitaxel synthesis from precursor compounds and methods of producing the same
AU695530B2 (en) 1993-02-05 1998-08-13 Bryn Mawr College Synthesis of taxol, analogs and intermediates with variable a-ring side chains
US5684175A (en) 1993-02-05 1997-11-04 Napro Biotherapeutics, Inc. C-2' hydroxyl-benzyl protected, N-carbamate protected (2R, 3S)- 3-phenylisoserine and production process therefor
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
RU2118177C1 (ru) 1993-08-02 1998-08-27 Алексей Борисович Башкиров Способ индукции иммунного ответа организма
US5795560A (en) 1994-11-01 1998-08-18 Neorx Corporation Targeting protein-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5679807A (en) * 1995-01-30 1997-10-21 Hauser, Inc. Preparation of taxol and docetaxel through primary amines
DE19514087A1 (de) 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
US6015555A (en) 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5675025A (en) 1995-06-07 1997-10-07 Napro Biotherapeutics, Inc. Paclitaxel synthesis from precursor compounds and methods of producing the same
FR2741066B1 (fr) 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
AU2112697A (en) 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
US6107497A (en) 1996-02-29 2000-08-22 Napro Biotherapeutics, Inc. Intermediate for use in docetaxel synthesis and production method therefor
US5688977A (en) 1996-02-29 1997-11-18 Napro Biotherapeutics, Inc. Method for docetaxel synthesis
ES2151277T3 (es) 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US5973170A (en) 1996-09-25 1999-10-26 Napro Biotherapuetics, Inc. C-7 metal alkoxides of baccatin III
US5750737A (en) 1996-09-25 1998-05-12 Sisti; Nicholas J. Method for paclitaxel synthesis
WO1998019705A1 (en) 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Branched peptide linkers
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
WO1999022728A1 (en) * 1997-10-31 1999-05-14 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
US6545125B1 (en) 1997-11-18 2003-04-08 Chugai Seiyaku Kabushiki Kaisha Compounds with antitumor activity
US6066749A (en) 1998-05-01 2000-05-23 Napro Biotherapeutics, Inc. Method for conversion of C-2'-O-protected-10-hydroxy taxol to c-2'-O-protected taxol:useful intermediates in paclitaxel synthesis
US6048990A (en) 1998-05-01 2000-04-11 Napro Biotherapeutics, Inc. Method for selective acylation of C-2'-O-protected-10-hydroxy-taxol at the C-10 position
CA2362937C (en) 1999-02-24 2011-03-22 The Uab Research Foundation Taxane derivatives for targeted therapy of cancer
US6143902A (en) 1999-06-21 2000-11-07 Napro Biotherapeutics, Inc. C-2 hydroxyl protected-N-acyl (2R,3S)-3-phenylisoserine N-imido activated esters and method for production thereof
US6136999A (en) 1999-06-21 2000-10-24 Napro Biotherapeutics, Inc. C-2 hydroxyl protected-n-acyl (2R,3S)-3-phenylisoserine substituted phenyl activated esters and method for production thereof

Also Published As

Publication number Publication date
US6825166B2 (en) 2004-11-30
NO20034166D0 (no) 2003-09-19
WO2002076448A1 (en) 2002-10-03
EP1383492A1 (en) 2004-01-28
JP2010254696A (ja) 2010-11-11
IL157993A0 (en) 2004-03-28
US20050209174A1 (en) 2005-09-22
CA2441484A1 (en) 2002-10-03
AU2002254400B2 (en) 2007-08-09
US7153946B2 (en) 2006-12-26
EP1383492A4 (en) 2008-12-24
IL157993A (en) 2008-07-08
US20020198141A1 (en) 2002-12-26
JP2004528309A (ja) 2004-09-16

Similar Documents

Publication Publication Date Title
NO20034166L (no) Molekyl¶re konjugater for anvendelse ved behandling av cancer
IL251270A0 (en) Cancer treatment
NO20034877D0 (no) Anvendelse av bifosfonater ved behandling av benmetastase forbundet med prostatakreft
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EE05481B1 (et) Kinasoliini derivaadid kasvajate raviks
ITMI990375A1 (it) Trattamento del cancro co epotiloni
ATE430570T1 (de) Synergistische kombinationstherapie zur krebsbehandlung
NO20035609D0 (no) Fremgangsmåte for kontinuerlig naftabehandling
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
AR028476A1 (es) Tratamiento del cancer
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
SE0301854L (sv) Antiigensättningsbehandling
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
NO20014228L (no) Radioaktiv cisplatin i behandling av cancer
AU2002364890A8 (en) Molecules for disease detection and treatment
GB0026015D0 (en) Cancer treatment
IS8391A (is) Notkun á síramesíni við meðhöndlun á krabbameini
NO20040815L (no) Anvendelse av antroquinoner i behandling av nyresykdom.
AU2002359567A8 (en) Molecules for disease detection and treatment
AU2002248723A8 (en) Molecules for disease detection and treatment
EP1465633A4 (en) QUINAZOLINONE COMPOUNDS IN COMBINED FORMS FOR ENHANCED CANCER TREATMENT
NO20042166L (no) Kombinasjonsterapi for behandling av sykdom
NO20042850L (no) Kreftbehandling

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application